About: The impact of COVID-19 restrictions on needle and syringe programme provision and coverage in England

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The impact of COVID-19 restrictions on needle and syringe programme provision and coverage in England Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	The impact of COVID-19 restrictions on needle and syringe programme provision and coverage in England
Creator	Webster, Jane Whitfield, Mark Manager, Surveillance
source	Elsevier; Medline; PMC
abstract	BACKGROUND: The restrictions introduced in response to COVID-19 present many challenges, particularly for vulnerable and marginalised populations. These include maintaining access to Needle and Syringe Programmes (NSPs) to reduce the harms associated with injecting drugs. NSPs effectiveness is coverage dependent, but lockdowns and social distancing limit NSP access and availability. The impact on NSP provision in England is explored using enhanced monitoring data. METHOD: Data collected through an established comprehensive monitoring system from five four-week periods, centred on the implementation of restrictions in the UK in mid-March 2020, are examined. Weekly averages are compared to allow for public holidays and weekly variation in activity. RESULTS: The restrictions resulted in the number of NSP clients decreasing by 36%, visits by 36%, and needles distributed by 29%. NSP coverage for those injecting psychoactive drugs halved, declining from 14 needles per-week during the 4-weeks to 15(th) March 2020 to 7 needles per-week by mid-April, and coverage has remained at this level since then. CONCLUSIONS: Though it is currently unclear if there has been a decline in injecting, the decline in NSP coverage is so marked that it almost certainly reflects decreased utilisation among those in need, indicating increased equipment reuse and risk.
has issue date	2020-07-15(xsd:dateTime)
bibo:doi	10.1016/j.drugpo.2020.102851
bibo:pmid	32736959
has license	no-cc
sha1sum (hex)	a351cffa5e22df674ffe89bce432a03293fdea76
schema:url	https://doi.org/10.1016/j.drugpo.2020.102851
resource representing a document's title	The impact of COVID-19 restrictions on needle and syringe programme provision and coverage in England
has PubMed Central identifier	PMC7362866
has PubMed identifier	32736959
schema:publication	Int J Drug Policy
resource representing a document's body	covid:a351cffa5e22df674ffe89bce432a03293fdea76#body_text
is schema:about of	named entity 'Words' named entity 'needle' named entity 'England' named entity 'England' named entity 'hygiene' named entity 'living on the streets' named entity 'social distancing' named entity 'IPED' named entity 'COVID-19' named entity 'social distancing' named entity 'NICE' named entity 'England' named entity 'COVID' named entity 'psychoactive drugs' named entity 'key worker' named entity 'Syringe' named entity 'soft tissue' named entity '16 March' named entity 'COVID-19' named entity 'HIV' named entity 'March 2020' named entity 'people who inject drugs' named entity 'pharmacies' named entity 'people who inject drugs' named entity 'HCV' named entity 'people who inject drugs' named entity 'PHE' named entity 'England' named entity 'opiates' named entity 'HIV' named entity 'PHE' named entity 'living on the streets' named entity 'people who inject drugs' named entity 'IPED' named entity 'psychoactive drugs' named entity 'social distancing' named entity 'social distancing' named entity 'COVID-19 restrictions' named entity 'psychoactive drugs' named entity 'social distancing' named entity 'psychoactive drugs' named entity 'EMCDDA' named entity 'North West of England' named entity 'psychoactive' named entity 'social distancing' named entity 'coronavirus pandemic' named entity 'England' named entity 'COVID' named entity 'Merseyside' named entity 'opiate' named entity 'emergency departments' named entity 'psychoactive drugs' named entity 'local resilience forums' named entity 'psychoactive' named entity 'COVID-19 restrictions' named entity 'EMCDDA' named entity 'psychoactive drugs' named entity 'data quality assurance' named entity 'MHCLG' named entity '16 March' named entity '23 March' named entity 'psychoactive drugs' named entity 'pharmacies' named entity 'data set' named entity 'March 2020' named entity 'blood-borne' named entity 'COVID' named entity 'Cheshire' named entity 'social distancing' named entity 'drug administration' named entity 'ECDC' named entity 'coronavirus' named entity 'coronavirus' named entity 'North West of England' named entity 'coronavirus' named entity 'viral infections' named entity 'HCV' named entity 'social distancing' named entity 'opioid substitution therapy'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software